# HMRlignan (Norway spruce extract)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hmrlignan
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Picea abies L. extract, Norway spruce knot extract, 7-hydroxymatairesinol, HMR lignan, Spruce lignan extract, Hydroxymatairesinol

## Overview

HMRlignan is a purified form of 7-hydroxymatairesinol (HMR), a plant lignan extracted from Norway spruce (Picea abies) knots, which the gut microbiota converts to the mammalian lignan enterolactone. This enterolactone acts as a selective estrogen receptor modulator (SERM), binding estrogen receptors with weak agonist or antagonist activity depending on the hormonal environment.

## Health Benefits

• Hormone balance support through phytoestrogen activity that modulates estrogen receptors in a protective manner (mechanistic evidence) • [Cardiovascular health](/ingredients/condition/heart-health) support through LDL cholesterol reduction and [anti-inflammatory](/ingredients/condition/inflammation) effects (observational lignan research) • Potential breast and prostate cancer risk reduction (observational studies on dietary lignans) • [Immunomodulatory](/ingredients/condition/immune-support) activity demonstrated in vitro (PMID: 20005303) • [Antioxidant protection](/ingredients/condition/antioxidant) through conversion to enterolactone metabolites (mechanistic evidence)

## Mechanism of Action

HMRlignan (7-hydroxymatairesinol) is metabolized by intestinal bacteria, primarily Clostridium scindens and related species, into enterolactone, a mammalian lignan with SERM activity. Enterolactone competitively binds estrogen receptors ERα and ERβ with preferential affinity for ERβ, modulating gene transcription in a tissue-selective manner that may limit estrogen-driven cell proliferation. Additionally, enterolactone inhibits aromatase (CYP19A1) enzyme activity, reducing local estrogen biosynthesis, and exerts antioxidant effects by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and upregulating Nrf2-mediated antioxidant pathways.

## Clinical Summary

A randomized, double-blind, placebo-controlled trial in 22 postmenopausal women demonstrated that 36 mg/day of HMRlignan for 8 weeks significantly raised serum enterolactone levels compared to placebo, confirming reliable bioconversion. Observational epidemiological studies associating high enterolactone levels with reduced [LDL cholesterol](/ingredients/condition/heart-health) and lower [inflammatory](/ingredients/condition/inflammation) markers (CRP) provide indirect cardiovascular evidence, though intervention trials specifically using HMRlignan for lipid outcomes remain limited in size and number. Preclinical and mechanistic data support potential roles in hormone-sensitive cancer risk reduction, but no large-scale RCTs have confirmed this in humans. Overall, evidence for enterolactone elevation is strong; evidence for downstream clinical endpoints such as cardiovascular disease or cancer risk reduction requires larger interventional studies.

## Nutritional Profile

{"macronutrients": {"fiber": "Present in trace amounts, specific concentration not well-documented"}, "micronutrients": {"vitamins": "Not a significant source of vitamins", "minerals": "Not a significant source of minerals"}, "bioactive_compounds": {"lignans": "High concentration, primarily 7-hydroxymatairesinol (HMR), typically around 80-90% of total lignans", "phytoestrogens": "Present due to lignan content, contributing to estrogen receptor modulation"}, "bioavailability_notes": "Lignans are metabolized by intestinal bacteria into enterolignans, which are absorbed and exert biological effects. Bioavailability can vary based on gut microbiota composition."}

## Dosage & Preparation

No clinically studied dosage ranges are specified for HMRlignan in human trials. The ingredient is standardized to contain not less than 90% HMR potassium acetate complex and is typically formulated in capsules or softgels. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

HMRlignan is generally well tolerated at doses of 36–72 mg/day, with no serious adverse events reported in short-term clinical studies; mild gastrointestinal discomfort has been noted occasionally. Due to its SERM and aromatase-inhibiting activity, HMRlignan should be used cautiously by individuals taking hormone-sensitive medications, including tamoxifen, aromatase inhibitors (anastrozole, letrozole), or hormone replacement therapy, as pharmacodynamic interactions may alter efficacy. Individuals with estrogen receptor-positive (ER+) cancers should consult an oncologist before use, as the net estrogenic or anti-estrogenic effect in vivo depends on systemic hormone levels. Safety data in pregnancy and lactation are insufficient, and use is not recommended in these populations.

## Scientific Research

Clinical evidence for HMRlignan specifically is limited, with only one identified in vitro study (PMID: 20005303) demonstrating [immunomodulatory](/ingredients/condition/immune-support) activity. While manufacturers reference upcoming data on [anti-inflammatory](/ingredients/condition/inflammation) effects for heart health and enlarged prostate, no completed human RCTs are detailed in current literature. Evidence primarily draws from observational studies on general dietary lignan intake.

## Historical & Cultural Context

HMRlignan as an isolated compound is a modern nutraceutical discovered in the 1990s-2000s with no direct traditional medicine use. However, lignan-rich plants like flaxseed, sesame, and whole grains have been consumed across cultures for reproductive health, digestive balance, and [cardiovascular](/ingredients/condition/heart-health) wellness.

## Synergistic Combinations

Flaxseed lignans, Green tea extract, Resveratrol, DIM (diindolylmethane), Saw palmetto

## Frequently Asked Questions

### What is the effective dosage of HMRlignan?

Clinical studies have used 36 mg/day of HMRlignan (standardized 7-hydroxymatairesinol from Norway spruce knot extract) to reliably elevate serum enterolactone levels in postmenopausal women. Some protocols use up to 72 mg/day for enhanced enterolactone conversion, though dose-response data above 36 mg remain limited. HMRlignan supplements are typically taken once daily with food to support absorption and gut microbiota conversion.

### How does HMRlignan increase enterolactone levels?

After oral ingestion, intestinal bacteria including Clostridium scindens metabolize 7-hydroxymatairesinol (HMR) through a two-step biotransformation: first to matairesinol, then to enterodiol, and finally to enterolactone. This conversion occurs primarily in the colon, which means antibiotic use or low gut microbiome diversity can significantly reduce enterolactone production from HMRlignan. Serum enterolactone peaks approximately 8–10 hours after ingestion.

### Can men take HMRlignan supplements?

Yes, men can take HMRlignan; in males, elevated enterolactone levels have been associated epidemiologically with reduced prostate cancer risk and favorable PSA profiles, though intervention trials are lacking. The aromatase-inhibiting effect of enterolactone may modestly reduce estradiol conversion in men, which could be relevant for those with elevated estrogen levels. Men on androgen deprivation therapy or aromatase inhibitor treatments for prostate cancer should consult a physician before supplementing.

### Is HMRlignan the same as flaxseed lignans?

No — HMRlignan provides 7-hydroxymatairesinol (HMR) derived from Norway spruce knot extract, whereas flaxseed lignans primarily supply secoisolariciresinol diglucoside (SDG). Both are plant lignans that the gut converts to enterolactone and enterodiol, but HMRlignan is considered a more direct precursor to enterolactone, typically yielding higher and more consistent serum enterolactone levels per milligram than SDG-based flaxseed supplements. The two may be complementary but are not interchangeable.

### Does HMRlignan interact with tamoxifen or hormone therapy?

HMRlignan's active metabolite enterolactone shares overlapping mechanisms with tamoxifen — both act on estrogen receptors and influence CYP19A1 aromatase activity — raising the theoretical possibility of additive or antagonistic pharmacodynamic interactions. In vitro studies suggest enterolactone can compete with tamoxifen at ERα binding sites, though clinical interaction data in humans are not yet available. Patients undergoing tamoxifen therapy, aromatase inhibitor treatment, or hormone replacement therapy should discuss HMRlignan supplementation with their oncologist or prescribing physician before starting.

### What foods naturally contain HMRlignan or similar lignans to HMRlignan?

HMRlignan is a branded extract derived from Norway spruce wood, which is not commonly found in typical dietary foods. However, similar plant lignans are naturally abundant in flaxseeds, sesame seeds, whole grains, legumes, and berries, though these contain different lignan profiles and compounds than the concentrated spruce extract. If you rely on food sources alone, achieving the lignan levels studied in HMRlignan research would require consistent daily consumption of lignan-rich foods, which is why supplementation is often preferred for targeted support.

### Who should avoid HMRlignan supplementation?

Women with a personal or strong family history of estrogen-sensitive cancers should consult their healthcare provider before using HMRlignan due to its phytoestrogenic activity, even though research suggests protective rather than promotional effects. Individuals taking selective estrogen receptor modulators (SERMs) or other hormone-modulating medications should seek medical guidance to rule out potential interactions. Pregnant and nursing women should avoid HMRlignan supplements unless specifically recommended by their healthcare provider, as safety data in these populations is limited.

### How strong is the clinical evidence supporting HMRlignan for breast and prostate health?

Most evidence for HMRlignan's role in cancer risk reduction comes from observational studies on dietary lignans rather than randomized controlled trials specifically on HMRlignan itself, which means correlation has been observed but causation is not definitively established. Animal and mechanistic studies demonstrate that lignans can modulate estrogen receptor activity in ways theoretically protective against hormone-dependent cancers, but human clinical trials directly testing HMRlignan for these outcomes remain limited. For cancer prevention claims, HMRlignan should be viewed as a complementary support rather than a standalone treatment, and individuals with cancer concerns should prioritize evidence-based medical approaches.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*